Bullboard - Stock Discussion Forum Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Add To Watchlist

OTCQB:CYTOF - Post Discussion

Altamira Therapeutics Ltd > CYTO...no wonder there was a little pop & vol ; )

View:

Post by Iseneschal on Jan 24, 2024 11:45am

CYTO...no wonder there was a little pop & vol ; )

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

2024-01-08 05:47 ET - News Release

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) --

Altamira Therapeutics to Present at 3^rd Annual mRNA-Based Therapeutics Summit

Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy

HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3^rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.